Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
MEDPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
MedPlus Health Services' subsidiary, Optival Health Solutions Private Limited, received a suspension order on May 20, 2025, from the Assistant Director, Drugs Control Administration, Bangalore Circle-Tumkur, Karnataka. The order suspends the drug license of a single store located at SSIT College Road, Karnataka, for three days under Rule 65 of the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945. The company has disclosed a potential revenue loss of approximately Rs 1.78 lakhs from this suspension. The order pertains to only one store out of MedPlus's extensive retail network across India.
The financial impact is negligible at Rs 1.78 lakhs for a company of MedPlus's scale, and the suspension is limited to a single store for just three days. This is a routine regulatory compliance matter unlikely to have any material effect on the company's operations, earnings, or stock price.